Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Hardee, Matthew E., Murat O. Arcasoy, Kimberly L. Blackwell, John P. Kirkpatrick, and Mark W. Dewhirst. “Erythropoietin biology in cancer.” Clin Cancer Res 12, no. 2 (January 15, 2006): 332–39. https://doi.org/10.1158/1078-0432.CCR-05-1771.

PMID
16428469
Full Text

Craciunescu, O., T. Raidy, D. Brizel, K. Blackwell, Z. Vujaskovic, T. Wong, E. Jones, N. Larrier, J. Macfall, and M. Dewhirst. “SU‐FF‐J‐125: Therapy Assessment Using a Full Time Point (fTP) Pharmacokinetic Analysis of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging (DCE‐MRI): Role of Region of Interest (ROI) Selection in Three Tumor Sites.” In Medical Physics, 33:2049, 2006. https://doi.org/10.1118/1.2240901.

Full Text

Hardee, M. E., J. P. Kirkpatrick, S. Shan, S. A. Snyder, Z. Vujaskovic, Z. N. Rabbani, M. W. Dewhirst, and K. L. Blackwell. “Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis.” Br J Cancer 93, no. 12 (December 12, 2005): 1350–55. https://doi.org/10.1038/sj.bjc.6602846.

PMID
16288305
Full Text

Craciunescu, O. I., E. L. Jones, K. L. Blackwell, T. Z. Wong, E. L. Rosen, Z. Vujaskovic, J. R. MacFall, et al. “Characterizing tumor changes during neoadjuvant treatment of locally advanced breast cancer patients (LABC) using dynamicenhanced magnetic resonance imaging (DE-MRI).” Progress in Biomedical Optics and Imaging  Proceedings of Spie 5698 (August 16, 2005): 116–25. https://doi.org/10.1117/12.591173.

Full Text

Burris, Howard A., Herbert I. Hurwitz, E Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O’Neil, Paul K. Marcom, et al. “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.” J Clin Oncol 23, no. 23 (August 10, 2005): 5305–13. https://doi.org/10.1200/JCO.2005.16.584.

PMID
15955900
Full Text

Spector, Neil L., Wenle Xia, Howard Burris, Herbert Hurwitz, E Claire Dees, Afshin Dowlati, Bert O’Neil, et al. “Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.” J Clin Oncol 23, no. 11 (April 10, 2005): 2502–12. https://doi.org/10.1200/JCO.2005.12.157.

PMID
15684311
Full Text

Daniel, B. R., and K. Blackwell. “Ectopic breast cancer: Rare, treatable, and potentially curable.” Community Oncology 2, no. 2 (January 1, 2005): 120–22. https://doi.org/10.1016/S1548-5315(11)70864-6.

Full Text

Chu, Isabel, Kimberly Blackwell, Susie Chen, and Joyce Slingerland. “The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.” Cancer Res 65, no. 1 (January 1, 2005): 18–25.

PMID
15665275
Scholars@Duke

Craciunescu, O., K. Blackwell, T. Wong, E. Rosen, T. Raidy, E. Jones, Z. Vujaskovic, et al. “SU‐EE‐A2‐06: Non‐Contact, Non‐Invasive Breast Thermography Has Potential to Evaluate Treatment Response in Breast Cancer Patients.” In Medical Physics, 32:1898, 2005. https://doi.org/10.1118/1.1997458.

Full Text

Rosen, E. L., K. L. Blackwell, J. A. Baker, and S. G. Orel. “Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.” Breast Diseases 15, no. 2 (July 1, 2004): 140–42.

Scholars@Duke

Pages